by Martina | Sep 28, 2026 | News
A new population study published in Redox Biology has established reference ranges for NAD and glutathione in whole blood from healthy adults. The study was led by researchers at the University of Helsinki, with NADMED co-authors. The reference ranges are based on 330...
by Martina | Jun 23, 2026 | Blog
NAD⁺ drives cellular energy production as well as the function of several metabolic enzymes, and researchers are constantly discovering more about its connections to cancer, diabetes, Alzheimer’s, and a wide range of other health conditions. Meanwhile, your patients...
by Martina | May 8, 2026 | Blog
What makes NAD⁺ so special is that its concentration in human tissues can be influenced both internally and externally, through the body’s own metabolic activity and through dietary supplementation. This makes it especially interesting in the context of aging and...
by Martina | Apr 29, 2026 | News
NADMED has appointed James Lee as its new Chief Executive Officer, effective from the beginning of May. His appointment supports the company’s next phase of international growth and expansion. Lee brings over 25 years of experience in global pharma and healthcare,...
by Martina | Mar 31, 2026 | News
We are proud to announce that Dr. Keyue Sun and the Schlegel Lab have been selected as the inaugural recipients of the NADMED Award for their work on metabolic assessment of organ viability in transplantation. Their research tackles a critical question in transplant...